Your browser is no longer supported. Please, upgrade your browser.
Settings
MACK Merrimack Pharmaceuticals, Inc. daily Stock Chart
MACK [NASD]
Merrimack Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.79 Insider Own3.36% Shs Outstand13.38M Perf Week1.51%
Market Cap44.32M Forward P/E- EPS next Y- Insider Trans94.13% Shs Float12.95M Perf Month1.51%
Income-10.60M PEG- EPS next Q- Inst Own52.70% Short Float4.10% Perf Quarter-12.92%
Sales- P/S- EPS this Y65.00% Inst Trans-2.02% Short Ratio20.60 Perf Half Y6.98%
Book/sh1.30 P/B2.59 EPS next Y- ROA- Target Price4.00 Perf Year-28.06%
Cash/sh- P/C- EPS next 5Y5.60% ROE- 52W Range1.49 - 5.51 Perf YTD6.98%
Dividend- P/FCF- EPS past 5Y27.50% ROI- 52W High-38.79% Beta2.57
Dividend %- Quick Ratio8.30 Sales past 5Y- Gross Margin- 52W Low126.17% ATR0.19
Employees- Current Ratio8.30 Sales Q/Q- Oper. Margin- RSI (14)51.25 Volatility5.31% 5.48%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.43 Prev Close3.31
ShortableYes LT Debt/Eq0.00 EarningsAug 20 BMO Payout0.00% Avg Volume25.75K Price3.37
Recom3.50 SMA202.16% SMA501.04% SMA2002.52% Volume11,106 Change1.81%
Oct-07-16Downgrade JP Morgan Overweight → Neutral
May-27-16Initiated Robert W. Baird Neutral $8
Dec-23-15Reiterated Mizuho Buy $16 → $13
Oct-27-15Reiterated Oppenheimer Outperform $13 → $15
Apr-21-15Reiterated Mizuho Buy $13 → $16
Oct-10-14Resumed Oppenheimer Outperform $9 → $11
Jul-08-14Resumed Brean Capital Buy $16
Jun-20-14Reiterated Oppenheimer Outperform $10 → $8.50
Aug-09-13Reiterated Oppenheimer Outperform $12 → $10
Jun-25-13Initiated Mizuho Buy $12
May-08-12Initiated Oppenheimer Outperform $12
Aug-07-20 08:20AM  
Aug-05-20 08:33AM  
May-07-20 06:10PM  
Apr-02-20 08:30AM  
Feb-07-20 11:14AM  
Dec-22-19 07:44PM  
Dec-03-19 09:15AM  
08:45AM  
Oct-28-19 06:04AM  
Sep-24-19 04:45PM  
Sep-19-19 03:23PM  
09:00AM  
Aug-26-19 11:27AM  
09:00AM  
Aug-22-19 08:30AM  
Aug-16-19 09:15AM  
Jul-25-19 08:30AM  
May-31-19 07:34AM  
06:21AM  
May-30-19 04:05PM  
May-10-19 07:30AM  
May-06-19 01:46PM  
May-03-19 05:43PM  
Apr-18-19 03:07PM  
Apr-16-19 04:15PM  
Apr-12-19 01:57PM  
Apr-09-19 05:50PM  
Apr-08-19 10:12AM  
Apr-05-19 08:29AM  
07:48AM  
Apr-04-19 05:58PM  
04:15PM  
Mar-07-19 09:06AM  
Mar-06-19 07:00AM  
Feb-12-19 07:35AM  
Feb-11-19 09:39AM  
Jan-28-19 10:19PM  
Dec-10-18 05:00PM  
Nov-09-18 10:31AM  
08:45AM  
Nov-08-18 10:17AM  
Nov-07-18 06:45AM  
Nov-06-18 01:44PM  
Nov-05-18 07:55AM  
Oct-31-18 04:05PM  
Oct-24-18 11:19AM  
Oct-19-18 10:48AM  
07:46AM  
06:00AM  
Oct-16-18 07:30AM  
Oct-11-18 05:16PM  
Sep-20-18 07:00AM  
Sep-06-18 10:35AM  
06:50AM  
Sep-05-18 12:06PM  
Sep-04-18 10:07AM  
Aug-16-18 08:00AM  
Aug-08-18 10:20AM  
Aug-07-18 08:18AM  
06:30AM  
06:30AM  
Aug-01-18 12:09PM  
Jul-31-18 04:10PM  
Jul-10-18 04:55PM  
Jul-02-18 04:15PM  
Jun-27-18 08:12AM  
Jun-26-18 07:51PM  
08:12AM  
Jun-25-18 07:55AM  
07:54AM  
07:29AM  
07:20AM  
Jun-15-18 08:41AM  
Jun-07-18 09:15AM  
Jun-04-18 01:57PM  
May-29-18 08:15AM  
07:00AM  
May-09-18 10:49AM  
May-08-18 06:25AM  
May-03-18 10:13AM  
May-01-18 07:00AM  
Apr-09-18 07:30AM  
Apr-04-18 08:15AM  
Mar-14-18 07:30AM  
Mar-13-18 09:45AM  
Mar-12-18 07:06PM  
07:30AM  
06:27AM  
06:25AM  
Mar-05-18 07:00AM  
Feb-27-18 05:11AM  
Feb-26-18 06:55AM  
Feb-23-18 09:10AM  
Feb-20-18 07:00AM  
Feb-15-18 07:00AM  
Feb-06-18 08:25AM  
Jan-04-18 08:00AM  
Dec-11-17 04:12AM  
Nov-30-17 06:50AM  
Nov-20-17 08:04PM  
Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Levy Noah G.DirectorJul 22Buy3.11177,274552,087796,365Jul 24 06:59 PM
Andersen EricDirectorJul 22Buy3.11177,274552,086819,446Jul 24 06:59 PM
CROCKER GARY LSee RemarksJul 22Sale3.0975,546233,5620Jul 24 07:03 PM
CROCKER GARY LSee RemarksJul 22Sale3.08117,963362,9030Jul 24 07:03 PM
Andersen EricDirectorApr 21Buy3.251,4244,628692,768Apr 22 02:27 PM
Levy Noah G.DirectorApr 21Buy3.251,4244,628693,014Apr 22 02:30 PM
Levy Noah G.DirectorApr 20Buy3.252,3257,556692,181Apr 22 02:30 PM
Andersen EricDirectorApr 20Buy3.252,3257,556691,344Apr 22 02:27 PM
Andersen EricDirectorApr 07Buy3.035,89917,885689,019Apr 08 05:40 PM
Levy Noah G.DirectorApr 07Buy3.035,89917,885690,821Apr 08 05:37 PM
Levy Noah G.DirectorApr 06Buy3.006,04218,105687,370Apr 07 07:24 PM
Andersen EricDirectorApr 06Buy3.006,04318,108683,120Apr 07 07:23 PM
Andersen EricDirectorApr 03Buy2.6010,75027,924677,077Apr 07 07:23 PM
Levy Noah G.DirectorApr 03Buy2.5910,75027,877683,835Apr 07 07:24 PM